SweetValueLab
Write for us

Incyte Corporation — Intrinsic Value & Fair Price

INCY
NASDAQHealthcareBiotechnologyCIK 0000879169incyte.comAbout INCY
Valuation grade ?B
Quant grade ?S
Last close · Oct 30, 2026120.39+3.59 (+3.07%)
Model value · DCF · Perpetuity growth · 5y
88.79
Incyte closed at $120.39 — overvalued by 36% vs model.
78.33the model's range104.05

DCF · Perpetuity growth · 5y leads for profitable growth — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.

Other models
25.00 – 167.42
Wall St. target
152.00 21% below
Above model, 1y
15 of 30 days

How it is valued

Valued asProfitable Growth
Moderate growth (~18% recent)High profitability (25% net margin)Highly cyclical earningsStrong FCF yield (5.5%)
What growth the price implies: the reverse DCF

Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.